Virtu Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Virtu Financial’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$460K	Buy	+149,722	New	+$579K	0.02%	605
2025 Q3	–	Sell	-449,092	Closed	-$2.27M	–	2003
2025 Q2	$2.27M	Buy	449,092 +415,056	+1,219%	+$2.04M	0.12%	146
2025 Q1	$180K	Buy	+34,036	New	+$248K	0.01%	837
2024 Q4	–	Sell	-37,512	Closed	-$247K	–	1989
2024 Q3	$247K	Sell	37,512 -17,014	-31%	-$122K	0.01%	713
2024 Q2	$409K	Sell	54,526 -11,915	-18%	-$104K	0.03%	498
2024 Q1	$662K	Buy	+66,441	New	+$740K	0.05%	333
2023 Q3	–	Sell	-27,205	Closed	-$203K	–	1812
2023 Q2	$203K	Buy	+27,205	New	+$190K	0.02%	809

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Virtu Financial's RXRX Position: Q1 2026 in Review

Virtu Financial opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 149,722 shares worth $460K. The stake represents 0.02% of the portfolio and ranks #605 among its holdings. This is a return to the name: Virtu Financial previously reported a position in RXRX as recently as Q2 2025.

Virtu Financial first reported a position in RXRX in Q2 2023 and has held it in 7 quarters since. The position peaked at $2.27M in Q2 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Virtu Financial held 149,722 shares of Recursion Pharmaceuticals worth $460K as of Q1 2026.
Recursion Pharmaceuticals was a new Virtu Financial position in Q1 2026.
Recursion Pharmaceuticals made up 0.02% of Virtu Financial's portfolio in Q1 2026, its #605 holding.
Virtu Financial first reported a position in Recursion Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
Virtu Financial's Recursion Pharmaceuticals position peaked at $2.27M in Q2 2025.
335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.